JP2010510202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510202A5 JP2010510202A5 JP2009536817A JP2009536817A JP2010510202A5 JP 2010510202 A5 JP2010510202 A5 JP 2010510202A5 JP 2009536817 A JP2009536817 A JP 2009536817A JP 2009536817 A JP2009536817 A JP 2009536817A JP 2010510202 A5 JP2010510202 A5 JP 2010510202A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazol
- ethyl
- methyl
- carboxamide
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 cyano, hydroxy Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- YMNAJWHTELQUJU-UHFFFAOYSA-N quinoline-6-carboxamide Chemical compound N1=CC=CC2=CC(C(=O)N)=CC=C21 YMNAJWHTELQUJU-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- QXALUNHYJJONQH-UHFFFAOYSA-N 1,1,1-trifluoro-2-methylpropane Chemical compound CC(C)C(F)(F)F QXALUNHYJJONQH-UHFFFAOYSA-N 0.000 claims 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- LLPQXWLGZAACIC-UHFFFAOYSA-N 2-[5-methyl-4-[1-[[2-(1,1,1-trifluoro-2-methylpropan-2-yl)quinoline-6-carbonyl]amino]ethyl]pyrazol-1-yl]acetic acid Chemical compound C=1C=C2N=C(C(C)(C)C(F)(F)F)C=CC2=CC=1C(=O)NC(C)C=1C=NN(CC(O)=O)C=1C LLPQXWLGZAACIC-UHFFFAOYSA-N 0.000 claims 1
- YAOHVFBANTYDOB-UHFFFAOYSA-N 6-tert-butyl-n-[(1,3,5-trimethylpyrazol-4-yl)methyl]naphthalene-2-carboxamide Chemical compound CC1=NN(C)C(C)=C1CNC(=O)C1=CC=C(C=C(C=C2)C(C)(C)C)C2=C1 YAOHVFBANTYDOB-UHFFFAOYSA-N 0.000 claims 1
- IDODWMLPQCEBLC-UHFFFAOYSA-N 6-tert-butyl-n-[(1,3-dimethylpyrazol-4-yl)methyl]naphthalene-2-carboxamide Chemical compound CC1=NN(C)C=C1CNC(=O)C1=CC=C(C=C(C=C2)C(C)(C)C)C2=C1 IDODWMLPQCEBLC-UHFFFAOYSA-N 0.000 claims 1
- DLCOKHZYWRQXHW-UHFFFAOYSA-N 6-tert-butyl-n-[(1,5-dimethylpyrazol-4-yl)methyl]naphthalene-2-carboxamide Chemical compound C1=NN(C)C(C)=C1CNC(=O)C1=CC=C(C=C(C=C2)C(C)(C)C)C2=C1 DLCOKHZYWRQXHW-UHFFFAOYSA-N 0.000 claims 1
- CEHCNURWOYLZMF-UHFFFAOYSA-N 6-tert-butyl-n-[(1-methylpyrazol-4-yl)methyl]naphthalene-2-carboxamide Chemical compound C1=NN(C)C=C1CNC(=O)C1=CC=C(C=C(C=C2)C(C)(C)C)C2=C1 CEHCNURWOYLZMF-UHFFFAOYSA-N 0.000 claims 1
- BSQXNYAVXBOMPG-UHFFFAOYSA-N 6-tert-butyl-n-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]naphthalene-2-carboxamide Chemical compound CC1=NNC(C)=C1CNC(=O)C1=CC=C(C=C(C=C2)C(C)(C)C)C2=C1 BSQXNYAVXBOMPG-UHFFFAOYSA-N 0.000 claims 1
- OFCPLRFKZPMIJB-UHFFFAOYSA-N 6-tert-butyl-n-[1-(1,5-dimethylpyrazol-4-yl)ethyl]naphthalene-2-carboxamide Chemical compound C=1C=C2C=C(C(C)(C)C)C=CC2=CC=1C(=O)NC(C)C=1C=NN(C)C=1C OFCPLRFKZPMIJB-UHFFFAOYSA-N 0.000 claims 1
- BYGSPSKHVWUUDQ-UHFFFAOYSA-N 6-tert-butyl-n-[1-(1,5-dimethylpyrazol-4-yl)propyl]naphthalene-2-carboxamide Chemical compound C=1C=C2C=C(C(C)(C)C)C=CC2=CC=1C(=O)NC(CC)C=1C=NN(C)C=1C BYGSPSKHVWUUDQ-UHFFFAOYSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000006430 alkyl cyclopropyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 208000030500 lower respiratory tract disease Diseases 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- IZROQLNXTZBVPM-UHFFFAOYSA-N n-[1-(1,5-dimethylpyrazol-4-yl)ethyl]-6-(1,1,1-trifluoro-2-hydroxypropan-2-yl)naphthalene-2-carboxamide Chemical compound C=1C=C2C=C(C(C)(O)C(F)(F)F)C=CC2=CC=1C(=O)NC(C)C=1C=NN(C)C=1C IZROQLNXTZBVPM-UHFFFAOYSA-N 0.000 claims 1
- MZCMFVNDWIHJPZ-UHFFFAOYSA-N n-[1-(1,5-dimethylpyrazol-4-yl)ethyl]-6-(1,1,1-trifluoro-2-methoxypropan-2-yl)naphthalene-2-carboxamide Chemical compound C1=CC2=CC(C(C)(OC)C(F)(F)F)=CC=C2C=C1C(=O)NC(C)C=1C=NN(C)C=1C MZCMFVNDWIHJPZ-UHFFFAOYSA-N 0.000 claims 1
- LHMXUZUBFHYLHP-UHFFFAOYSA-N n-[1-(1,5-dimethylpyrazol-4-yl)ethyl]-6-(1-methylcyclopropyl)naphthalene-2-carboxamide Chemical compound C1=NN(C)C(C)=C1C(C)NC(=O)C(C=C1C=C2)=CC=C1C=C2C1(C)CC1 LHMXUZUBFHYLHP-UHFFFAOYSA-N 0.000 claims 1
- VMDBHQHMTLNLFG-UHFFFAOYSA-N n-[1-(1,5-dimethylpyrazol-4-yl)ethyl]-6-(2-hydroxypropan-2-yl)naphthalene-2-carboxamide Chemical compound C=1C=C2C=C(C(C)(C)O)C=CC2=CC=1C(=O)NC(C)C=1C=NN(C)C=1C VMDBHQHMTLNLFG-UHFFFAOYSA-N 0.000 claims 1
- JQYVZGWQJLUPAT-UHFFFAOYSA-N n-[1-(1,5-dimethylpyrazol-4-yl)ethyl]-6-(trifluoromethyl)naphthalene-2-carboxamide Chemical compound C=1C=C2C=C(C(F)(F)F)C=CC2=CC=1C(=O)NC(C)C=1C=NN(C)C=1C JQYVZGWQJLUPAT-UHFFFAOYSA-N 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000011479 upper respiratory tract disease Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 0 *C(*)(c1c(*)[n](*)nc1*)NC(C(*1)=CC=C2C1=CC=C(*)*2)=O Chemical compound *C(*)(c1c(*)[n](*)nc1*)NC(C(*1)=CC=C2C1=CC=C(*)*2)=O 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86628506P | 2006-11-17 | 2006-11-17 | |
| US94393307P | 2007-06-14 | 2007-06-14 | |
| US98334307P | 2007-10-29 | 2007-10-29 | |
| PCT/IB2007/003559 WO2008059370A2 (en) | 2006-11-17 | 2007-11-09 | Substituted bicyclocarboxyamide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510202A JP2010510202A (ja) | 2010-04-02 |
| JP2010510202A5 true JP2010510202A5 (enExample) | 2010-12-24 |
Family
ID=39311049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536817A Withdrawn JP2010510202A (ja) | 2006-11-17 | 2007-11-09 | 置換ビシクロカルボキシアミド化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7964732B2 (enExample) |
| EP (1) | EP2091944B1 (enExample) |
| JP (1) | JP2010510202A (enExample) |
| AR (1) | AR064253A1 (enExample) |
| AT (1) | ATE509925T1 (enExample) |
| CA (1) | CA2669915C (enExample) |
| CL (1) | CL2007003289A1 (enExample) |
| GT (1) | GT200700103A (enExample) |
| PE (1) | PE20081504A1 (enExample) |
| TW (1) | TW200831089A (enExample) |
| UY (1) | UY30723A1 (enExample) |
| WO (1) | WO2008059370A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| JP5745505B2 (ja) | 2009-05-07 | 2015-07-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | バニロイド受容体リガンドとしての置換フェニル尿素および置換フェニルアミド |
| CA2758289A1 (en) * | 2009-05-07 | 2010-11-11 | Gruenenthal Gmbh | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| WO2012025469A1 (en) * | 2010-08-24 | 2012-03-01 | Solvay Sa | Improved process for the preparation of esters of 1-h-pyrazole-4-carboxylic acids |
| WO2012062463A1 (en) * | 2010-11-10 | 2012-05-18 | Grünenthal GmbH | Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands |
| JP5140776B1 (ja) * | 2012-09-05 | 2013-02-13 | タマ化学工業株式会社 | １−置換−３−フルオロアルキルピラゾール−４−カルボン酸エステルの製造方法 |
| BR122020001830B1 (pt) | 2015-05-18 | 2023-02-28 | Shenyang Sinochem Agrochemicals R&D Co., LTD | Compostos pirazol substituídos contendo pirimidinila, preparação e aplicação dos mesmos |
| AR112673A1 (es) | 2017-08-11 | 2019-11-27 | Syngenta Participations Ag | Derivados de pirazol activos como plaguicidas |
| WO2020164993A1 (en) | 2019-02-13 | 2020-08-20 | Syngenta Crop Protection Ag | Pesticidally active pyrazole derivatives |
| WO2020164994A1 (en) | 2019-02-13 | 2020-08-20 | Syngenta Crop Protection Ag | Pesticidally active pyrazole derivatives |
| CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
| CN110734401A (zh) * | 2019-10-10 | 2020-01-31 | 长沙麓兴生物科技有限公司 | 一种氮未取代-4-甲酰基吡唑的制备方法 |
| CN114989546B (zh) * | 2022-07-05 | 2023-07-28 | 上海乐纯生物技术有限公司 | 一种用于细胞治疗储液袋生产的fep膜 |
| WO2025172368A1 (en) | 2024-02-13 | 2025-08-21 | Syngenta Crop Protection Ag | (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025210095A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline compounds |
| WO2026022173A1 (en) | 2024-07-26 | 2026-01-29 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2671059B2 (ja) | 1990-11-30 | 1997-10-29 | 富士レビオ株式会社 | ナフトエ酸誘導体 |
| WO1994003432A1 (en) | 1992-08-07 | 1994-02-17 | The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services | Polyhydroxylated naphthyl 2-carboxylate, and quinolyl and isoquinolyl 3-carboxylate derivatives as protein tyrosine kinase inhibitors |
| AU674613B2 (en) | 1993-09-28 | 1997-01-02 | Otsuka Pharmaceutical Co., Ltd. | Quinoxaline derivative as antidiabetic agent |
| DE4423353A1 (de) | 1994-07-04 | 1996-01-11 | Bayer Ag | Verfahren zur Herstellung N-acylierter 2-Chlor-5-aminomethylpyridine |
| US5753700A (en) | 1994-12-28 | 1998-05-19 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US6979686B1 (en) * | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| AU1457299A (en) | 1997-11-12 | 1999-05-31 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
| WO1999026927A2 (en) | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| ATE494388T1 (de) | 1999-01-13 | 2011-01-15 | Univ New York State Res Found | Neues verfahren zum erschaffen von proteinkinase- inhibitoren |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| IL145922A0 (en) | 1999-04-28 | 2002-07-25 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
| CA2374820A1 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| CN1361768A (zh) | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
| US6855715B1 (en) | 1999-06-14 | 2005-02-15 | Eli Lilly And Company | Serine protease inhibitors |
| EP1206446B1 (de) | 1999-08-07 | 2004-05-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| DE19963179B4 (de) | 1999-12-27 | 2009-02-05 | Grünenthal GmbH | Substituierte 1- und 2-Naphthol-Mannichbasen |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| WO2002016318A1 (en) | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| US7259157B2 (en) | 2001-04-03 | 2007-08-21 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists |
| WO2002085908A1 (en) | 2001-04-24 | 2002-10-31 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| TWI239942B (en) | 2001-06-11 | 2005-09-21 | Dainippon Pharmaceutical Co | N-arylphenylacetamide derivative and pharmaceutical composition containing the same |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| CA2455754A1 (en) | 2001-07-31 | 2003-02-20 | Bayer Healthcare Ag | Amine derivatives |
| DE60226756D1 (de) | 2001-10-04 | 2008-07-03 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| EP1438973A4 (en) | 2001-10-05 | 2005-07-13 | Ono Pharmaceutical Co | MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS |
| CA2464214C (en) | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOCHINOLINVERBINDUNGEN |
| AR038420A1 (es) | 2002-02-15 | 2005-01-12 | Glaxo Group Ltd | Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende |
| US8163769B2 (en) | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| TW200306159A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides |
| GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003231370A1 (en) | 2002-04-18 | 2003-10-27 | Institute Of Medicinal Molecular Design. Inc. | Amide derivatives |
| US20060106102A1 (en) | 2002-06-07 | 2006-05-18 | Eric Morand | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) |
| GB2389580A (en) | 2002-06-12 | 2003-12-17 | Bayer Ag | 2-Naphthamide PGI2 antagonists |
| AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| AU2003295782A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers |
| AU2003294441A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| US7179427B2 (en) * | 2002-11-25 | 2007-02-20 | Abb Lummus Global Inc. | Apparatus for countercurrent contacting of gas and solids |
| AU2003287878A1 (en) | 2002-12-11 | 2004-06-30 | 7Tm Pharma A/S | Quinoline compounds for use in mch receptor related disorders |
| AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
| TW200505450A (en) | 2003-02-03 | 2005-02-16 | Janssen Pharmaceutica Nv | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| WO2004078114A2 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| CA2518398A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| NZ543274A (en) | 2003-05-14 | 2007-12-21 | Emisphere Tech Inc | Compositions for delivering peptide YY and PYY agonists |
| EP1628661A2 (en) * | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| JP4638423B2 (ja) | 2003-06-20 | 2011-02-23 | ガルデルマ・リサーチ・アンド・デヴェロップメント | ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用 |
| KR100707123B1 (ko) | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
| CA2532064A1 (en) | 2003-07-15 | 2005-02-03 | Merck & Co., Inc. | Hydroxypyridine cgrp receptor antagonists |
| SE0302323D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| CA2536788A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| US20050232818A1 (en) * | 2003-09-19 | 2005-10-20 | Donald Sandell | Single sheet seal applicator and cartridge |
| EP1669348A4 (en) | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7553848B2 (en) | 2004-01-23 | 2009-06-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2007524673A (ja) | 2004-01-23 | 2007-08-30 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドと治療におけるその使用 |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| CN1976907A (zh) | 2004-04-30 | 2007-06-06 | 武田药品工业株式会社 | 杂环酰胺化合物及其作为mmp－13抑制剂的用途 |
| WO2006016548A1 (ja) | 2004-08-09 | 2006-02-16 | Eisai R & D Management Co., Ltd. | ヘテロ環化合物を含有する新規な抗マラリア剤 |
-
2007
- 2007-11-09 JP JP2009536817A patent/JP2010510202A/ja not_active Withdrawn
- 2007-11-09 WO PCT/IB2007/003559 patent/WO2008059370A2/en not_active Ceased
- 2007-11-09 EP EP07825705A patent/EP2091944B1/en not_active Not-in-force
- 2007-11-09 US US12/063,159 patent/US7964732B2/en not_active Expired - Fee Related
- 2007-11-09 CA CA2669915A patent/CA2669915C/en not_active Expired - Fee Related
- 2007-11-09 AT AT07825705T patent/ATE509925T1/de not_active IP Right Cessation
- 2007-11-15 PE PE2007001571A patent/PE20081504A1/es not_active Application Discontinuation
- 2007-11-15 CL CL200703289A patent/CL2007003289A1/es unknown
- 2007-11-16 AR ARP070105111A patent/AR064253A1/es unknown
- 2007-11-16 TW TW096143519A patent/TW200831089A/zh unknown
- 2007-11-16 GT GT200700103A patent/GT200700103A/es unknown
- 2007-11-16 UY UY30723A patent/UY30723A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2669915A1 (en) | Substituted bicyclocarboxyamide compounds | |
| CA2656875A1 (en) | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds | |
| JP2021532124A5 (enExample) | ||
| CA2600409A1 (en) | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds | |
| JP2009536918A5 (enExample) | ||
| HRP20210472T1 (hr) | Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4 | |
| JP2011508784A5 (enExample) | ||
| HRP20220362T1 (hr) | Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitori irak4 | |
| JP2019512532A5 (enExample) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2012523430A5 (enExample) | ||
| EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
| CA2645257A1 (en) | Sulfonyl benzimidazole derivatives | |
| JP2013543896A5 (enExample) | ||
| HRP20191756T1 (hr) | Spirociklički inhibitori katepsina c | |
| JP2013531028A5 (enExample) | ||
| JP2010513478A5 (enExample) | ||
| JP2017528506A5 (enExample) | ||
| JP2011528658A5 (enExample) | ||
| JP2016503786A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2023514872A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| NZ596585A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase |